entertainment -WSS

entertainment

author：focus 2025-10-01 10:52:02 - browse：4423

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Activists slam private health insurers over coverage restrictions

hotspot

WSS

Moonlake's readout produced a cash windfall. Risks remain

The cancer drug shortage isn’t new — and neither are the solutions

Senate committee scrutinizes Medicare Advantage brokers

HHS leader on health, climate change and biopharma emissions

Jerome Adams on the need for new antivirals for Covid

Dobbs anniversary: the lost opportunity of abortion as health care

focus

entertainment

explore

The cancer drug shortage isn’t new — and neither are the solutions

Medical records are filled with copy

Affirmative action in medical school literally saved lives

In age of alternative facts, a scholarly course on calling out crap

Hollywood unions extend contract negotiations for actors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Guidelines to prevent youth baseball injuries need more muscle

FDA struggles to regulate food additives, sometimes for decades

New air purifier tech could be key to improving indoor air quality

At least 13 dead in Texas as scorching temps continue

entertainment

STAT Summit: Michael J. Fox on progress in Parkinson's research

Senate committee scrutinizes Medicare Advantage brokers

FDA warns J&J's Abiomed: We will regulate your software

After affirmative action ruling, medical educators look to 'holistic review'

FDA warns J&J's Abiomed: We will regulate your software

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

hotspot

explore

knowledge